Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 42 (66.7%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases

NCT01254240
completedphase_4

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

NCT00940862
completedphase_4

Narrow-Band UVB-Therapy in Psoriasis

NCT00748020

Clinical Trials (3)

Showing 3 of 3 trials
NCT01254240Phase 2

Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases

Completed
NCT00940862Phase 4

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Completed
NCT00748020Phase 4

Narrow-Band UVB-Therapy in Psoriasis

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3